Trial Profile

Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary)
Indications Advanced breast cancer; Early breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Breast 54

Most Recent Events

03 Jul 2025 Planned number of patients changed from 48 to 32.
03 Jul 2025 Planned End Date changed from 1 Jan 2026 to 1 Feb 2030.
03 Jul 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Sep 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com